120666-53-7

Basic information

• Product Name: Cbz-(R)-Phenylglycinol
• Synonyms: (R)-2-benzyloxycarbonylamino-2-phenylethanol; (R)-2-hydroxy-1-phenyl-ethyl)-carbamic acid benzyl ester
• CAS NO: 120666-53-7
• Molecular Formula: C₁₆H₁₇NO₃
• Molecular Weight: 271.32
• Mol File: 120666-53-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Cbz-(R)-Phenylglycinol(CAS DataBase Reference)
• NIST Chemistry Reference: Cbz-(R)-Phenylglycinol(120666-53-7)
• EPA Substance Registry System: Cbz-(R)-Phenylglycinol(120666-53-7)

Safety Data

• Hazardous Substances Data: 120666-53-7(Hazardous Substances Data)

Upstream product

• 100-42-5 styrene 
• 621-84-1 O-benzyl carbamate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 56613-80-0 D-2-phenylglycinol 
• 86217-38-1 4-phenyl-2-oxazolidinone 
• 501-53-1 benzyl chloroformate 
• 20989-17-7 Phenylglycinol 
• 91174-01-5 sodium [(benzyloxy)carbonyl]chloroamide 

Downstream Products

• 128900-61-8 3-vinyl-(S)-4-phenyl-2-oxazolidinone 
• 130406-64-3 [(S)-1-((R)-2-Amino-2-phenyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-1-methyl-ethyl]-carbamic acid adamantan-2-yl ester 
• 130406-64-3 tricyclo<3.3.1.1^3,7>dec-2-yl *,R^*)>-<2-<(2-amino-2-phenylethyl)amino>-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl>carbamate 
• 130406-35-8 N^β-<(benzyloxy)carbonyl>-(R)-β-amino-2-phenylethanamine 
• 130406-70-1 *,S^*)>-4-<<2-<<3-(1H-indol-3-yl)-2-methyl-1-oxo-2-<<(tricyclo<3.3.1.1^3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>-1-phenylethyl>amino>-4-oxobutanoic acid 
• 130332-27-3 N-{(R)-2-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-1-phenyl-ethyl}-succinamic acid 
• 130406-68-7 *,R^*)>-5-<<2-<<3-(1H-indol-3-yl)-2-methyl-1-oxo-2-<<(tricyclo<3.3.1.1^3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>-1-phenylethyl>amino>-5-oxopentanoic acid 
• 130406-65-4 tricyclo<3.3.1.1^3,7>dec-2-yl *,R^*)>-3-(1H-indol-3-ylmethyl)-3-methyl-4,9,12-trioxo-7-phenyl-13-oxa-2,5,8-triazatetradec-10-enoate 
• 130406-66-5 tricyclo<3.3.1.1^3,7>dec-2-yl *,R^*)>-3-(1H-indol-3-ylmethyl)-3-methyl-4,9,11-trioxo-7-phenyl-12-oxa-2,5,8-triazatridecanoate 
• 130406-72-3 *,R^*)>-3-<<2-<<3-(1H-indol-3-yl)-2-methyl-1-oxo-2-<<(tricyclo<3.3.1.1^3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>-1-phenylethyl>amino>-3-oxopropanoic acid 
• 130406-67-6 PD 136450 
• 160695-26-1 (4R)-3-propionyl-4-phenyl-1,3-oxazolidin-2-one 
• 130406-37-0 toluene-4-sulfonic acid (R)-2-benzyloxycarbonylamino-2-phenyl-ethyl ester 

Relevant articles and documents

Cinchona alkaloid ester derivatives as ligands in the asymmetric dihydroxylation and aminohydroxylation of alkenes

Cinchona alkaloid ester derivatives were adopted to asymmetric dihydroxylation and asymmetric aminohydroxylation reactions in excellent yields and enantiomeric excesses.

ALKYLNITRILE QUINOLINES, AS NK-3 RECEPTOR LIGANDS

Compounds of Formula (I) wherein R 1 , A, 2 , R 3 , R 4 , R 5 , n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom

The present invention relates to spiroimidazolidine derivatives of the formula I in which E, V, W, X, R1and R2have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, such as, for example, rheumatoid arthritis, or allergic disorders. The compounds of the formula I are also inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention also relates to processes for the preparation of the compounds of the formula I, pharmaceutical preparations which contain compounds of the formula I, and methods for treating these disorders.